This activity is supported by an independent educational grant from Lilly. This online educational programme has been designed for healthcare professionals worldwide, except in the United Kingdom.
This CME-accredited micro masterclass on alcohol use disorders (AUD) explores how evidence-based guidance can be applied in local practice. Using a clinical case, discover practical approaches to diagnosis, treatment planning, monitoring and coordinated care, while identifying ways to overcome local service barriers.
Session Highlights
- Identify and diagnose AUD: Apply validated screening tools and document diagnoses effectively.
- Individualise treatment: Align treatment goals and medication choices with patient needs and local guidance.
- Coordinate care: Strengthen referral pathways, monitoring and escalation between services.
- Apply evidence locally: Identify practical changes to improve care despite resource and system constraints.
Target Audience:
Healthcare professionals involved in the screening, diagnosis, treatment and ongoing management of alcohol use disorders, including primary care clinicians, psychiatrists, mental health professionals and addiction specialists.
Faculty
Dr. Néstor Szerman, MD
Complutense University of Madrid, Spain, is internationally recognised for his expertise in addictions and dual disorders. His career has been dedicated to advancing research and treatment in this field. He currently practises at the Complutense University of Madrid, Spain, and he was the Founding President of the Spanish Society of Dual Disorders (2005-2016) and is President of the World Association on Dual Disorders (WADD) (2024-2027), Chair of the WPA Section on Dual Disorders, President of the Dual Disorders Foundation (since 2016) and Co-Director “catedra patologia dual” Francisco de Vitoria University, Spain.
Disclosures
Partners for Advancing Clinical Education (Partners) requires every individual in a position to control educational content to disclose all financial relationships with ineligible companies that have occurred within the past 24 months. Ineligible companies are organizations whose primary business is producing, marketing, selling, re-selling, or distributing healthcare products used by or on patients.
All relevant financial relationships for anyone with the ability to control the content of this educational activity are listed below and have been mitigated according to Partners policies. Others involved in the planning of this activity have no relevant financial relationships.
Dr. Néstor Szerman, MD faculty for this educational activity, has the following relevant financial relationships: Consultant and/or Advisor Gedeon Richter/Recordati, Lundbeck and Eli Lilly
Joint Accreditation Statement
In support of improving patient care, this activity has been planned and implemented by Partners for Advancing Clinical Education (Partners) and MedAll. Partners is jointly accredited by the Accreditation Council for Continuing Medical Education (ACCME), the Accreditation Council for Pharmacy Education (ACPE), and the American Nurses Credentialing Center (ANCC), to provide continuing education for the healthcare team.
Physician Continuing Education
Partners designates this enduring material for a maximum of 0.5 AMA PRA Category 1 Credit(s)™. Physicians should claim only the credit commensurate with the extent of their participation in the activity.
Nursing Continuing Professional Development
The maximum number of hours awarded for this Nursing Continuing Professional Development activity is 0.5 ANCC contact hours.
Pharmacy Continuing Education
Partners designates this continuing education activity for 0.5 contact hour(s) (0.5 CEUs) of the Accreditation Council for Pharmacy Education.
Universal Activity Number - JA4008073-9999-26-391-H01-P
Type of Activity: Knowledge
PA Continuing Medical Education
Partners has been authorized by the American Academy of PAs (AAPA) to award AAPA Category 1 CME credit for activities planned in accordance with AAPA CME Criteria. This activity is designated for 0.5 AAPA Category 1 CME credits. Approval is valid until September 25th 2027. PAs should only claim credit commensurate with the extent of their participation.
Disclosure of Unlabeled Use
This educational activity may contain discussion of published and/or investigational uses of agents that are not indicated by the FDA. The planners of this activity do not recommend the use of any agent outside of the labeled indications. The opinions expressed in the educational activity are those of the faculty and do not necessarily represent the views of the planners. Please refer to the official prescribing information for each product for discussion of approved indications, contraindications, and warnings.
Disclaimer
Participants have an implied responsibility to use the newly acquired information to enhance patient outcomes and their own professional development. The information presented in this activity is not meant to serve as a guideline for patient management. Any procedures, medications, or other courses of diagnosis or treatment discussed or suggested in this activity should not be used by clinicians without evaluation of their patient’s conditions and possible contraindications and/or dangers in use, review of any applicable manufacturer’s product information, and comparison with recommendations of other authorities.
This continuing education activity is active starting November 17th 2026, and will expire on September 25th 2027.
Estimated time to complete this activity: 30 Minutes